A Multicenter Study to Evaluate the Effects of a 91-day Oral Contraceptive on Bone Mineral Density in Adolescent Females
Public ClinicalTrials.gov record NCT00924560. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Open-Label, Randomized, Controlled Study to Compare the Effects on Bone Mineral Density of DR-105 and a 28-Day Cycle Oral Contraceptive Regimen in Healthy, Postmenarchal, Adolescent Females
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study is being conducted to compare the effects of a 91-day oral contraceptive (OC) to a 28-day OC regimen on bone mineral density (BMD) in adolescent females.
Study identification
- NCT ID
- NCT00924560
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 1,361 participants
Conditions and interventions
Conditions
Interventions
Drug
Eligibility (public fields only)
- Age range
- 12 Years to 18 Years
- Sex
- Female
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 2009 (Type not available)
- Primary completion
- Aug 2012 (Actual)
- Completion
- Aug 2012 (Actual)
- Last update posted
- Oct 22, 2014
2009 – 2012
United States locations
- U.S. sites
- 46
- U.S. states
- 22
- U.S. cities
- 42
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Teva Investigational Site 007 | Phoenix | Arizona | — | — |
| Teva Investigational Site 018 | Phoenix | Arizona | — | — |
| Teva Investigational Site 005 | Tucson | Arizona | — | — |
| Teva Investigational Site 047 | North Little Rock | Arkansas | — | — |
| Teva Investigational Site 027 | La Mesa | California | — | — |
| Teva Investigational Site 040 | Los Angeles | California | — | — |
| Teva Investigational Site 037 | Mountain View | California | — | — |
| Teva Investigational Site 013 | San Diego | California | — | — |
| Teva Investigational Site 017 | San Diego | California | — | — |
| Teva Investigational Site 025 | Torrance | California | — | — |
| Teva Investigational Site 022 | Washington D.C. | District of Columbia | — | — |
| Teva Investigational Site 004 | Boynton Beach | Florida | — | — |
| Teva Investigational Site 008 | Clearwater | Florida | — | — |
| Teva Investigational Site 026 | DeLand | Florida | — | — |
| Teva Investigational Site 001 | Miami | Florida | — | — |
| Teva Investigational Site 003 | Miami | Florida | — | — |
| Teva Investigational Site 028 | Tampa | Florida | — | — |
| Teva Investigational Site 041 | West Palm Beach | Florida | — | — |
| Teva Investigational Site 034 | Champaign | Illinois | — | — |
| Teva Investigational Site 023 | Louisville | Kentucky | — | — |
| Teva Investigational Site 021 | Baton Rouge | Louisiana | — | — |
| Teva Investigational Site 030 | St Louis | Missouri | — | — |
| Teva Investigational Site 009 | Lincoln | Nebraska | — | — |
| Teva Investigational Site 010 | Lawrenceville | New Jersey | — | — |
| Teva Investigational Site 038 | Port Jefferson | New York | — | — |
| Teva Investigational Site 048 | Rochester | New York | — | — |
| Teva Investigational Site 002 | Durham | North Carolina | — | — |
| Teva Investigational Site 043 | Kernersville | North Carolina | — | — |
| Teva Investigational Site 044 | New Bern | North Carolina | — | — |
| Teva Investigational Site 020 | Raleigh | North Carolina | — | — |
| Teva Investigational Site 006 | Winston-Salem | North Carolina | — | — |
| Teva Investigational Site 033 | Cleveland | Ohio | — | — |
| Teva Investigational Site 012 | Medford | Oregon | — | — |
| Teva Investigational Site 035 | Pittsburgh | Pennsylvania | — | — |
| Teva Investigational Site 039 | Pottstown | Pennsylvania | — | — |
| Teva Investigational Site 036 | Providence | Rhode Island | — | — |
| Teva Investigational Site 032 | Charleston | South Carolina | — | — |
| Teva Investigational Site 024 | Columbia | South Carolina | — | — |
| Teva Investigational Site 046 | Dallas | Texas | — | — |
| Teva Investigational Site 031 | Houston | Texas | — | — |
| Teva Investigational Site 045 | Houston | Texas | — | — |
| Teva Investigational Site 011 | Waco | Texas | — | — |
| Teva Investigational Site 015 | Salt Lake City | Utah | — | — |
| Teva Investigational Site 019 | Norfolk | Virginia | — | — |
| Teva Investigational Site 014 | Seattle | Washington | — | — |
| Teva Investigational Site 016 | Spokane | Washington | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00924560, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 22, 2014 · Synced Oct 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00924560 live on ClinicalTrials.gov.